Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

DCC antibody

This anti-DCC antibody is a Mouse Monoclonal antibody detecting DCC in WB and IHC (f). Suitable for Human. This Primary Antibody has been cited in 6+ publications.
Catalog No. ABIN967443

Quick Overview for DCC antibody (ABIN967443)

Target

See all DCC Antibodies
DCC (Deleted in Colorectal Carcinoma (DCC))

Reactivity

  • 40
  • 35
  • 14
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
Human

Host

  • 49
  • 2
Mouse

Clonality

  • 49
  • 2
Monoclonal

Conjugate

  • 27
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
This DCC antibody is un-conjugated

Application

  • 36
  • 25
  • 14
  • 5
  • 5
  • 1
  • 1
Western Blotting (WB), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Clone

G97-449
  • Brand

    BD Pharmingen™

    Characteristics

    1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
    2. Please refer to us for technical protocols.
    3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

    Purification

    The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

    Immunogen

    Recombinant Human DCC

    Isotype

    IgG1
  • Application Notes

    Applications include western blot analysis (0.5 - 2.0 µg/ml). IMR-32 cells are suggested as a positive control. Other applications not routinely tested include flow cytometric analysis (titrate between 0.06-1.0 µg/one million cells). The antibody has also been published for immunohistochemistry of formalin-fixed, paraffin-embedded tissue sections. By western blot, DCC-specific antibodies typically identify protein species with molecular weights of approximately 175-190 kDa. Doublets in this range have been reported in brain. Several smaller immunoreactive species, representing degradation products, cross-reactive species, or DCC forms arising from alternative splicing of DCC mRNA or in vivo processing of the DCC protein may also be identified.

    Comment

    Related Products: ABIN967389

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    0.5 mg/mL

    Buffer

    Aqueous buffered solution containing ≤0.09 % sodium azide.

    Preservative

    Sodium azide

    Precaution of Use

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C

    Storage Comment

    Store undiluted at 4°C.
  • Huang, Chu, Hwang, Tsaur: "Coexpression of high-voltage-activated ion channels Kv3.4 and Cav1.2 in pioneer axons during pathfinding in the developing rat forebrain." in: The Journal of comparative neurology, Vol. 520, Issue 16, pp. 3650-72, (2012) (PubMed).

    Shibata, Reale, Lavin, Silverman, Fearon, Steele, Jessup, Loda, Summerhayes: "The DCC protein and prognosis in colorectal cancer." in: The New England journal of medicine, Vol. 335, Issue 23, pp. 1727-32, (1996) (PubMed).

    Reale, Hu, Zafar, Getzenberg, Levine, Fearon: "Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues." in: Cancer research, Vol. 54, Issue 16, pp. 4493-501, (1994) (PubMed).

    Fearon, Cho, Nigro, Kern, Simons, Ruppert, Hamilton, Preisinger, Thomas, Kinzler: "Identification of a chromosome 18q gene that is altered in colorectal cancers." in: Science (New York, N.Y.), Vol. 247, Issue 4938, pp. 49-56, (1990) (PubMed).

    Vogelstein, Fearon, Hamilton, Kern, Preisinger, Leppert, Nakamura, White, Smits, Bos: "Genetic alterations during colorectal-tumor development." in: The New England journal of medicine, Vol. 319, Issue 9, pp. 525-32, (1988) (PubMed).

    Fearon, Hamilton, Vogelstein: "Clonal analysis of human colorectal tumors." in: Science (New York, N.Y.), Vol. 238, Issue 4824, pp. 193-7, (1987) (PubMed).

  • Target

    DCC (Deleted in Colorectal Carcinoma (DCC))

    Alternative Name

    DCC

    Background

    One of the most common regions of allelic loss in colorectal tumors is chromosome 18, which is lost in more than 70% of carcinomas, and in almost 50% of late adenomas. This region of loss has been mapped to chromosome 18q and a gene called Deleted in Colorectal Cancer (DCC). DCC encodes an ~185 kDa glycoprotein with significant homology to the neural cell adhesion molecule and other related cell surface glycoproteins. The predicted amino acid sequence of DCC cDNA consists of a 1448 amino acid (aa) long transmembrane phosphoprotein. The extracellular domain consists of 1098 amino acids and has 42% sequence homology to cell adhesion proteins of the neural cell adhesion molecule (N-CAM) family. DCC mRNA is found to be expressed in normal colonic mucosa, but its expression is reduced or absent in the majority of colorectal carcinomas. The loss of heterozygosity and subsequent alteration of DCC expression has also been observed in tumors of non-colorectal origin. Clone G97-449 recognizes human DCC. A truncated recombinant protein containing the intracellular domain of the human DCC was used as immunogen.

    Molecular Weight

    175-190 kDa

    Pathways

    Regulation of Cell Size
You are here:
Chat with us!